Jushi Holdings Inc.
We are a vertically integrated, multi-state cannabis operator engaged in retail, distribution, cultivation, and processing operations in both medical and adult-use markets. We are focused on building a diverse portfolio of cannabis assets through opportunistic investments and pursuing application opportunities in attractive limited license jurisdictions.
C$0.69
-C$0.06 (-8.00%)
EOD Oct 16, 2026
Operating margin is thin at 1.85%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue growth slowed to 2.1%, essentially flat. Margins also contracted 2.4pp. This is a business that needs a catalyst.
Free cash flow declined 90% versus the prior year, cash generation momentum has weakened. Net debt of $269M represents 164.7x FCF, leverage limits flexibility.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$265M
▲ +2.1% YoY
Net Income (TTM)
-$71M
▼ -40.6% YoY
Op. Margin
3.13%
▼ -2.4pp YoY
ROIC
2.31%
▼ -1.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$4M
▼ -90.3% YoY
Op. Cash Flow (TTM)
$19M
▼ -17.8% YoY
Net Debt
$262M
Cash & Equiv.
$40M
5Y CAGR: +26.6%
Continue Research
SourceComputed from the 10-Q filed 12 May 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 3 Aug 2026. How this is calculated.
Price from market data, last close as of 16 Oct 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is Jushi Holdings (JUSHF) overvalued?
Jushi Holdings (JUSHF) trades above a two-stage DCF intrinsic value of about $-1.00 per share, so at $0.69 the stock looks overvalued (244.3% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Jushi Holdings scores 34/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
What is Jushi Holdings's fair value?+
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $-1.00 per share for JUSHF, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $-0.75. At today's $0.69, that puts the stock about 244.3% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Is Jushi Holdings a high-quality business?+
Jushi Holdings scores 34 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 3.1% operating margin and a 2.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Jushi Holdings a good stock to buy right now?+
That depends on valuation and quality together, not either alone. JUSHF currently trades above its estimated intrinsic value and scores 34/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Medicinal Chemicals & Botanical Products
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing JUSHF
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.